11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 27.04.2026 Expectation: 4800 pips
Silver sell-off with $70.0 target
Today at 11:21 AM 18
Period: 20.04.2026 Expectation: 870 pips
EURUSD enters corrective phase thanks to stronger dollar
Today at 10:14 AM 16
Period: 27.04.2026 Expectation: 170 pips
Selling SPX on US-Iran talks breakdown
Today at 09:47 AM 14
Period: 30.04.2026 Expectation: 1300 pips
Selling ​​SPX down to $6,630
Today at 06:42 AM 12
Period: 30.04.2026 Expectation: 1000 pips
Investing in EURUSD as eurozone inflation heats up
Today at 06:42 AM 16
Gold buy
Period: 20.04.2026 Expectation: 17000 pips
Gold offsets morning losses amid failed US-Iran negotiations
Today at 06:31 AM 29
Go to forecasts